Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Marts 2023

Genmab — Marts 2023

Planlagt Fastgjort Låst Flyttet Genmab
499 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #485

    Ja måske 🙂

    1 Reply Last reply
    0
    • P Offline
      P Offline
      Pensionisten
      wrote on sidst redigeret af
      #486

      Den optur, der startede 10. marts synes sat lidt på pause. Håber på lidt positivt nyt, der kan give fornyede kræfter.

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #487

        interesting, a new Epcoritamab trial +Venetoclax by the Haemato Oncology Foundation in the Netherlands, with Nordic & German CLL Study Groups, don't see genmab or abbvie - Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (AETHER) https://clinicaltrials.gov/ct2/show/NCT05791409

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #488

          Amivantamab efficacy in pretreated NSCLC with EGFR Exon 20 insertion mutations persists long term https://dailyreporter.esmo.org/european-lung-cancer-congress-2023/elcc-2023/amivantamab-efficacy-in-pretreated-nsclc-with-egfr-exon-20-insertion-mutations-persists-long-term

          1 Reply Last reply
          0
          • SolsenS Offline
            SolsenS Offline
            Solsen
            wrote on sidst redigeret af
            #489

            Rigtig spændende med combi med venetoclax, som er et fantastisk stof. Det kan der komme noget stort ud af for Genmab/Abbvie og patienterne.

            1 Reply Last reply
            0
            • StockBullS Offline
              StockBullS Offline
              StockBull
              wrote on sidst redigeret af
              #490

              Det er i vores mørkeste øjeblikke, at vi skal fokusere for at se lyset.

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #491

                Venetoclax is also from AbbVie if i am not mistaken...

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #492

                  Correct

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #493

                    In partnership with Roche/Genentech though

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #494

                      https://twitter.com/tnewsomdavis/status/1641480986746662913 "Very surprised that 1/3 of audience opted
                      for 1L Amivantamab"

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #495

                        Daratumumab, an anti-CD38 effective in two cases of severe refractory myositis https://www.institut-myologie.org/en/2023/03/30/daratumumab-an-anti-cd38-effective-in-two-cases-of-severe-refractory-myositis/

                        1 Reply Last reply
                        0
                        • StockBullS Offline
                          StockBullS Offline
                          StockBull
                          wrote on sidst redigeret af
                          #496

                          Morn, Fibonacci købssignal https://www.proinvestor.com/boards/111776/

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #497

                            https://onkologisktidsskrift.dk/behandlinger/lungekraeft/2835-nye-data-for-rybrevant-bekraefter-stoffets-potentiale-mod-egfr-exon-20-muteret-nsclc.html Nye data for Rybrevant bekræfter stoffets potentiale mod EGFR exon 20-muteret NSCLC

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #498

                              AMGEN on Horizon acquisition: We believe that our decades of leadership in inflammation and nephrology, combined with our global presence and world-class biologic capabilities, will enable us to reach many more patients with life-changing medicines like TAVNEOS and TEPEZZA than either company could achieve on its own. https://www.amgen.com/stories/2023/03/2022-letter-to-shareholders

                              1 Reply Last reply
                              0
                              • troldmandenT Offline
                                troldmandenT Offline
                                troldmanden
                                wrote on sidst redigeret af
                                #499

                                Nå mon vi skal have et positivt udfald af voldgift før 3000 kan brydes og agere ny bund. NPV impact er signifikant større på udfaldet af den afgørelse end af epco. Så bliver rart at komme på den anden side af retssagen. At få reduceret usikkerheden der tynger

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #500

                                  end of month & quarter. 4th red month in a row.

                                      • 28/2 18:07
                                        af E L
                                        3rd red month in a row. Since the lows of 2011 we only once had 4 negative months in a row, at the end of 2017
                                  1 Reply Last reply
                                  0

                                  Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                  Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                  With your input, this post could be even better 💗

                                  Tilmeld Log ind
                                  Svar
                                  • Svar som emne
                                  Login for at svare
                                  • Ældste til nyeste
                                  • Nyeste til ældste
                                  • Most Votes


                                  • Log ind

                                  • Har du ikke en konto? Tilmeld

                                  • Login or register to search.
                                  Powered by NodeBB Contributors
                                  • First post
                                    Last post
                                  0
                                  • Kategorier
                                  • Seneste
                                  • Etiketter
                                  • Populære
                                  • Verden
                                  • Bruger
                                  • Grupper